Dr. Reddy's Expands Collaboration To Market Amgen's 3 Medicines In India

(RTTNews) - Dr. Reddy's Laboratories Ltd (500124, DRREDDY, RDY) announced Friday that it has expanded its strategic collaboration to market and distribute three medicines of biotechnology company Amgen Inc. (AMGN)in India in the therapy areas of oncology and osteoporosis.

Under the terms of the collaboration, Dr. Reddy's will commercialise XGEVA (denosumab), Vectibix(panitumumab) and Prolia (denominate) in India.

XGEVA is a RANK ligand inhibitor and is approved in India for the prevention of skeletal related events in patients with advanced malignancies involving bone.

Vectibix is an epidermal growth factor receptor antagonist approved in India for the treatment of adult patients with wild-type KRAS metastatic colorectal cancer.

Prolia is a RANK ligand inhibitor approved in India for treatment of post-menopausal women with osteoporosis at high risk for fracture and also for treatment of increased bone mass in men with osteoporosis.

In 2015, Dr. Reddy's announced an initial strategic collaboration with Amgen to execute a full range of regulatory and commercial services to seek approval of and launch Amgen's Kyprolis (carfilzomib), BLINCYTO (blinatumomab) and Repatha (evolocumab) in India.